Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 72(2):203–218CrossRefPubMed
2.
Thakur V, Malhotra P, Lad D, Chatterjee D, Vinay K, Dogra S (2020) Ponatinib-induced lamellar ichthyosis-like eruption. Int J Dermatol 59(5):e156–e157CrossRefPubMed
3.
Brazzelli V, Grasso V, Borroni G (2013) Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 27(12):1471–1480CrossRefPubMed
4.
Mirali S, Abduelmula A, Mufti A, Sachdeva M, Yeung J (2021) Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review. J Cutan Med Surg 25(5):553–554CrossRefPubMedPubMedCentral
5.
Kaur S, Arora AK, Sekhon JS, Sood N (2015) Nilotinib-induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate. Indian J Dermatol Venereol Leprol 81(2):216–218CrossRefPubMed
Metadata
Title
Palmoplantar Keratoderma in a Patient of Chronic Myeloid Leukemia on Dasatinib
Authors
Priyansh Gupta
Priyanka Sangwan
Prabodha Kumar Das
Madhusmita Sethy
Biswanath Behera
Vishal Thakur
Publication date
01-04-2024
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-024-01754-6
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits